PFE · News · 20260822N

Patent Exclusivity Expiries

PFIZER INC · 2026-08-22 · Importance 36 · Surprise 42

Third-party reporting identified three notable Pfizer patent expirations expected through the end of 2028. These exclusivity losses create a medium-term risk of generic or biosimilar competition and potential revenue erosion. The digest did not identify the affected products or quantify the associated revenue exposure.

Key facts

• Pfizer faces three notable patent expirations through the end of 2028. source